- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00356889
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
A Phase II Trial of Bevacizumab and Erlotinib in Patients With Advanced Biliary Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Evaluate the objective response rate in patients with metastatic or unresectable cholangiocarcinoma treated with bevacizumab and erlotinib hydrochloride.
SECONDARY OBJECTIVES:
I. Evaluate time to progression in these patients.
II. Evaluate overall and progression-free survival of these patients.
III. Evaluate the adverse events associated with this regimen. OUTLINE: This is an open-label, multicenter study.
Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
After completion of study therapy, patients are followed periodically for up to 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Criteria:
- Absolute neutrophil count >= 1,500/mm3
Histologically or cytologically confirmed cholangiocarcinoma or gallbladder carcinoma:
- Metastatic or surgically unresectable disease
Measurable disease, defined as >= 1 lesion whose longest diameter can be accurately measured as >= 2.0 cm with conventional techniques or as > 1.0 cm with spiral CT scan:
- Spiral CT scan imaging must be used for pre- and post-treatment tumor measurements of lesions measuring >= 1.0 cm to < 2.0 cm
Clinical lesions will only be considered measurable when they are superficial
- Lesions on chest x-ray are acceptable as measurable lesions when they are clearly defined and surrounded by aerated lung
- No ampulla of Vater tumors
- No evidence of CNS disease
- Life expectancy >= 3 months
- ECOG performance status 0-2
- Platelet count >= 75,000/mm3
- Total bilirubin =< 2 times ULN
- ALT and AST =< 2.5 times ULN
- Creatinine =< 2 mg/dL
- Albumin >= 2.5 g/dL
- Alkaline phosphatase =< 5 times ULN
- Urine protein:creatinine ratio < 1.0 OR 24-hour urine protein < 1000 mg
No concurrent illness or medical condition, including any of the following:
- Impairment of gastrointestinal (GI) function or disease that may significantly alter the absorption of erlotinib hydrochloride
- Requirement for IV alimentation
No concurrent illness or medical condition, including any of the following:
- Active peptic ulcer disease;
- Serious or nonhealing wound, ulcer, or bone fracture;
- GI bleed that required procedural intervention within the past 3 months
No concurrent illness or medical condition, including any of the following:
- Abdominal fistula, GI perforation, or intra-abdominal abscess within the past 28 days
- Ongoing or active infection
- Symptomatic congestive heart failure
- Psychiatric illness or social situation that would limit study compliance
- No other malignancy within the past 3 years
- No abnormalities of the cornea
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No clinically significant cardiovascular disease
- More than 4 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered
- No significant traumatic injury within the past 28 days
- No prior systemic anticancer therapy for metastatic gallbladder or bile duct cancer
- More than 28 days since prior major surgery [Note: Insertion of a vascular access device is not considered major/minor surgery]
- More than 2 weeks since prior minor surgery [Note: Insertion of a vascular access device is not considered major/minor surgery]
- More than 7 days since prior core biopsy
- No concurrent major surgery
- No other concurrent chemotherapy, immunotherapy, radiotherapy, or any other therapy or supportive care considered investigational
- No concurrent enzyme-inducing antiepileptic drugs or any other CYP3A4 inducer, such as rifampin or Hypericum perforatum
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent investigational agents or other concurrent anticancer therapies
- No concurrent prophylactic hematopoietic colony-stimulating factors
Concurrent full-dose anticoagulants allowed provided PT/INR is > 1.5 and both of the following criteria are met:
- In-range INR on a stable dose of oral anticoagulant OR on a stable dose of low molecular weight heparin
- AND (continued from above) No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels, gastrointestinal ulcerations, or known varices)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bevacizumab and Erlotinib Hydrochloride
Patients receive 5 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15 and 150 mg oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Tumor tissue and blood specimens are collected periodically for correlative studies. Specimens are examined by immunohistochemistry for epidermal growth factor receptor (EGFR) and P-EGFR protein levels; AKT p-AKT, mitogen-activated protein kinase (MAPK) and P-MAPK protein levels; and vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 protein levels. EGFR mutations are detected by laser capture microdissection. Enzyme-linked immunosorbent assay is used to measure total and free serum VEGF levels. |
Given orally, 150 mg, once daily.
Other Names:
Given IV, 5mg/kg on days 1 and 15 every cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Confirmed Tumor Responses.
Time Frame: After 6 courses of treatment. Each course lasts 28 days.
|
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the target lesions. A confirmed tumor response is defined to be either a Complete Response or a Partial Response noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Confirmed tumor responses will be evaluated using the first 6 cycles of treatment. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment and had one post-baseline disease assessment will be evaluable for response. Forty-nine of the 53 eligible patients had at least one post-baseline disease assessment and were evaluable for this endpoint. |
After 6 courses of treatment. Each course lasts 28 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival Time
Time Frame: From registration to death due to any cause, assessed up to 3 years
|
Estimated using the method of Kaplan-Meier (1958).
|
From registration to death due to any cause, assessed up to 3 years
|
Time to Disease Progression
Time Frame: From registration to documentation of disease progression, assessed up to 3 years
|
Estimated using the method of Kaplan-Meier (1958).
|
From registration to documentation of disease progression, assessed up to 3 years
|
Duration of Response
Time Frame: From the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented, assessed up to 3 years
|
Point estimates and 95% confidence intervals were calculated using the method of Duffy and Santner (1987).
|
From the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented, assessed up to 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: William Schelman, Mayo Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Gallbladder Diseases
- Biliary Tract Diseases
- Bile Duct Diseases
- Biliary Tract Neoplasms
- Recurrence
- Gastrointestinal Neoplasms
- Cholangiocarcinoma
- Gallbladder Neoplasms
- Bile Duct Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Antibodies
- Erlotinib Hydrochloride
- Immunoglobulins
- Bevacizumab
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
Other Study ID Numbers
- NCI-2009-00115
- N01CM17104 (U.S. NIH Grant/Contract)
- MC044G
- CDR0000484566 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Cancer
-
Five Prime Therapeutics, Inc.CompletedGastric Cancer | Gastrointestinal Cancer | Gastrointestinal Cancer MetastaticUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); Dartmouth-Hitchcock Medical Center; West Virginia... and other collaboratorsActive, not recruitingGynecologic Cancer | Thoracic Cancer | Gastrointestinal Cancer | Other CancerUnited States
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, Germany; 4SC AGUnknownCancer | GI CancerUnited Kingdom
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC Utrecht; University of Cambridge; IRCCS Fondazione Stella MarisRecruitingGastrointestinal Cancer MetastaticNetherlands, United Kingdom, Italy
-
Bristol-Myers SquibbCompletedUpper Gastrointestinal CancerCanada
-
Sumitomo Pharma America, Inc.CompletedAdvanced Gastrointestinal CancerUnited States, Canada
-
University Medical Center GroningenCompleted
-
Goethe UniversityAgaplesion Markus Krankenhaus gGmbHCompletedAdvanced Gastrointestinal CancerGermany
-
Yonsei UniversitySmall and Medium Business AdministrationCompletedUpper Gastrointestinal CancerKorea, Republic of
-
Boehringer IngelheimCompletedGastrointestinal Cancer, MetastaticBelgium, United States, France, Japan, China
Clinical Trials on erlotinib hydrochloride
-
AVEO Pharmaceuticals, Inc.Biodesix, Inc.TerminatedNon-small Cell Lung CancerKorea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedMalignant Peritoneal MesotheliomaUnited States
-
University of California, DavisNational Cancer Institute (NCI); Novartis PharmaceuticalsCompletedRecurrent Non-small Cell Lung CancerUnited States
-
Merck Sharp & Dohme LLCCompleted
-
European Organisation for Research and Treatment...CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerFrance, Spain, Netherlands, Australia, United Kingdom, Italy, Portugal, Austria
-
The Cleveland ClinicUnknownBrain and Central Nervous System TumorsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedHead and Neck CancerSpain, United States
-
National Cancer Institute (NCI)NCIC Clinical Trials GroupCompletedEndometrial CancerCanada
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedGastric Cancer | Esophageal CancerUnited States, Canada